ARAF and Parkinson disease: Redenti et al. developed triazolotriazine-based dual GSK-3β/CK-1δ ligands as potential neuroprotective agents useful to treat PD, taking into account the involvement of GSK-3β in microglial-mediated inflammation and of the delta isoform of CK1 family of Ser/Thr kinases (CK-1δ) in the neuroinflammatory process, mainly through the Wnt and Hedgehog pathways, along with the crucial role of both PKs in the hyperphosphorylation of τ, α-syn, and parkin.